SCHEMBL3901283

SCHEMBL3901283

COC(=O)Nc1ccc(CC(O)C(=O)O)cc1

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.51
RAB9A P51151 3/20 0.50
NPC1 O15118 1/20 0.50
MAPT P10636 2/20 0.49
HPGD P15428 1/20 0.49
KDM6B O15054 1/20 0.46
KMT2A Q03164 1/20 0.44
FPR2 P25090 1/20 0.44
LDHA P00338 1/20 0.44
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 2/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8741875 1.00 SMN1; SMN2 (0.51) SMN1; SMN2RAB9ANPC1MAPTHPGD
SCHEMBL8366738 1.00 SMN1; SMN2 (0.51) SMN1; SMN2RAB9ANPC1MAPTHPGD
SCHEMBL28476992 0.87 SMN1; SMN2 (0.51) SMN1; SMN2RAB9ANPC1MAPTHPGD
SCHEMBL8366740 0.84 SMN1; SMN2 (0.43) SMN1; SMN2RAB9ANPC1MAPTHPGD
SCHEMBL22402969 0.82 SMN1; SMN2 (0.59) SMN1; SMN2RAB9ANPC1MAPTHPGD
SCHEMBL21552129 0.82 SMN1; SMN2 (0.59) SMN1; SMN2RAB9ANPC1MAPTHPGD
SCHEMBL10161781 0.81 SMN1; SMN2 (0.56) SMN1; SMN2RAB9ANPC1MAPTHPGD
SCHEMBL7217283 0.81 POLB (0.59) SMN1; SMN2RAB9ANPC1MAPTALDH1A1
SCHEMBL17202784 0.80 SMN1; SMN2 (0.57) SMN1; SMN2RAB9ANPC1MAPTHPGD
SCHEMBL17202644 0.79 SMN1; SMN2 (0.56) SMN1; SMN2RAB9ANPC1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112384511-B Endoparasite depsipeptides 硕腾服务有限责任公司 2024-01-30 CN disclosed
US-11786575-B2 Endoparasitic depsipeptides ZOETIS SERVICES LLC (US) 2023-10-17 US disclosed
US-11771738-B2 Endoparasitic depsipeptides ZOETIS SERVICES LLC (US) 2023-10-03 US disclosed
CN-111741956-B Antiparasitic depsipeptides 硕腾服务有限责任公司 2023-07-07 CN disclosed
US-20220211802-A1 Endoparasitic Depsipeptides ZOETIS SERVICES LLC 2022-07-07 US disclosed
US-11331369-B2 Endoparasitic depsipeptides ZOETIS SERVICES LLC (US) 2022-05-17 US disclosed
EP-3790876-A1 ENDOPARASITIC DEPSIPEPTIDES Zoetis Services LLC (US) 2021-03-17 EP disclosed
CN-112384511-A Endoparasitic depsipeptides 硕腾服务有限责任公司 2021-02-19 CN disclosed
EP-3717478-A1 ENDOPARASITIC DEPSIPEPTIDES Zoetis Services LLC (US) 2020-10-07 EP disclosed
US-20200282016-A1 Endoparasitic Depsipeptides ZOETIS SERVICES LLC 2020-09-10 US disclosed
WO-2019217449-A1 ENDOPARASITIC DEPSIPEPTIDES ZOETIS SERVICES LLC (US) 2019-11-14 WO disclosed
EP-0872481-B1 DEPSIPEPTIDE DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, AND NOVEL INTERMEDIATE THEREFOR ASTELLAS PHARMA INC (JP) 2009-03-18 EP disclosed
CN-1162409-C Depsipeptide deriv., its intermediate and method for preparing said intermediate ����ҩƷ��ҵ��ʽ���� 2004-08-18 CN disclosed
EP-0718293-B1 CYCLODEPSIPEPTIDE COMPOUND FUJISAWA PHARMACEUTICAL CO (JP) 2002-03-13 EP disclosed
CN-1071323-C process for producing depsipeptide derivative or salt thereof FUJISAWA PHARMACEUTICAL CO (JP) 2001-09-19 CN disclosed
CN-1309124-A Depsipeptide deriv., its intermediate and method for preparing said intermediate FUJISAWA PHARMACEUTICAL CO (JP) 2001-08-22 CN disclosed
EP-0872481-A1 DEPSIPEPTIDE DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, AND NOVEL INTERMEDIATE THEREFOR FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-10-21 EP disclosed
CN-1189159-A Depsipeptide derivative, process for producing the same, and novel intermediate thereof FUJISAWA PHARMACEUTICAL CO (JP) 1998-07-29 CN disclosed
US-5646244-A PARASITICIDES, ANTHELMINTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-07-08 US disclosed
EP-0718293-A1 CYCLODEPSIPEPTIDE COMPOUND FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-06-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11786575-B2 Endoparasitic depsipeptides VIP, PREP, NGLY1 SMN1; SMN2 3040/4885RAB9A 549/4885NPC1 893/4885
US-20200282016-A1 Endoparasitic Depsipeptides VIP, PREP, NGLY1 SMN1; SMN2 3040/4885RAB9A 549/4885NPC1 893/4885
US-20220211802-A1 Endoparasitic Depsipeptides VIP, PREP, NGLY1 SMN1; SMN2 3040/4885RAB9A 549/4885NPC1 893/4885
US-11771738-B2 Endoparasitic depsipeptides VIP, PREP, VIPR1 SMN1; SMN2 3783/4885RAB9A 901/4885NPC1 1035/4885
US-11331369-B2 Endoparasitic depsipeptides VIP, PREP, NGLY1 SMN1; SMN2 3040/4885RAB9A 549/4885NPC1 893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.